clinical trial · NCT07054190
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Breast CancerInavolisibRibociclibLetrozole
brief summary
This study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC).
started
Sep 9, 2025
primary completion
Jul 31, 2027
completion
Sep 28, 2027
last updated
Jul 16, 2026
official title
A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol